Liver International: 乳酸水平和器官衰竭的数量可以预测急性慢性肝功能衰竭患者的死亡率

2019-07-26 不详 MedSci原创

急性慢性肝功能衰竭(ACLF)患者的死亡率很高,而目前大多数预后评分不是针对重症监护室(ICU)的患者而开发的。本项研究的目的是改善预测ICU患者ACLF的危险分层。

背景和目的
急性慢性肝功能衰竭(ACLF)患者的死亡率很高,而目前大多数预后评分不是针对重症监护室(ICU)的患者而开发的。本项研究的目的是改善预测ICU患者ACLF的危险分层。

方法
研究人员对2010年至2016年间,来自Curry Cabral医院(葡萄牙)和阿尔伯塔医院(加拿大)的240名肝硬化和器官衰竭患者(慢性肝功能衰竭序贯器官衰竭评估评分[CLIF-SOFA])用于推导ICU死亡率的预后模型。使用2000年至2011年温哥华综合医院(加拿大)的237例肝硬化和器官衰竭患者来评估其预测模型的表现。

结果
在训练组的患者中,ICU和住院死亡率分别为39.2%和54.6%。ICU入院时乳酸中位数(4.4 vs 2.5 mmol / L)和器官衰竭数(3 vs 2)与ICU死亡率较高有关( P <0.001)。推导出乳酸和器官衰竭预测模型(LacOF)以预测ICU死亡率:-2.420 + 0.072×乳酸+ 0.569×器官衰竭数(曲线下面积[AUC],0.76)。在验证组中,LacOF模型判别能力(AUC 0.85)优于CLIF-SOFA(AUC,0.79),慢性肝衰竭急性-慢性肝功能衰竭(AUC,0.73),终末期肝病模型评分(AUC,0.78)和急性生理学和慢性健康评估II评分(AUC,0.74; P <0.05。)

结论
对于ACLF患者,入住ICU时乳酸和器官衰竭的数量可用于预测ICU死亡率。这种早期预后评估可能有助于更好地分层ICU死亡风险,从而优化器官支持策略。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883789, encodeId=c3951883e8943, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 04 20:28:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008749, encodeId=bd9d2008e4906, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Nov 01 22:28:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944885, encodeId=914519448857c, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Apr 18 22:28:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366725, encodeId=8d211366e259c, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 28 11:28:00 CST 2019, time=2019-07-28, status=1, ipAttribution=)]
    2020-03-04 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883789, encodeId=c3951883e8943, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 04 20:28:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008749, encodeId=bd9d2008e4906, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Nov 01 22:28:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944885, encodeId=914519448857c, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Apr 18 22:28:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366725, encodeId=8d211366e259c, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 28 11:28:00 CST 2019, time=2019-07-28, status=1, ipAttribution=)]
    2019-11-01 般若傻瓜
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883789, encodeId=c3951883e8943, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 04 20:28:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008749, encodeId=bd9d2008e4906, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Nov 01 22:28:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944885, encodeId=914519448857c, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Apr 18 22:28:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366725, encodeId=8d211366e259c, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 28 11:28:00 CST 2019, time=2019-07-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883789, encodeId=c3951883e8943, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 04 20:28:00 CST 2020, time=2020-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008749, encodeId=bd9d2008e4906, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Nov 01 22:28:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944885, encodeId=914519448857c, content=<a href='/topic/show?id=948a81192ea' target=_blank style='color:#2F92EE;'>#肝功能衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81192, encryptionId=948a81192ea, topicName=肝功能衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sat Apr 18 22:28:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366725, encodeId=8d211366e259c, content=<a href='/topic/show?id=8b4181188f5' target=_blank style='color:#2F92EE;'>#肝功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81188, encryptionId=8b4181188f5, topicName=肝功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 28 11:28:00 CST 2019, time=2019-07-28, status=1, ipAttribution=)]

相关资讯

Clin Trans Gastro: 肌肉减少症与接受经颈静脉肝内门体分流术的失代偿肝硬化急性慢性肝功能衰竭的发生有关

肌肉质量已被证明是肝硬化患者的预后标志物。肌肉减少症可以通过CT扫描获得的横向腰肌肌肉厚度通过身高(TPMT /身高)进行简单换算。它与急性慢性肝衰竭(ACLF)的关系尚未确定。ACLF与全身性炎症失调有关。本研究旨在评估肌肉减少症在接受经颈静脉肝内门体分流术(TIPS)的失代偿期肝硬化患者ACLF发展中的预测作用。

AP&T: 非选择性β受体阻滞剂增加肝硬化患者门静脉血栓形成的概率

非恶性门静脉血栓形成是肝硬化过程中的严重并发症,会影响肝移植的成功率,甚至影响外科手术后的存活率。因此,本项研究的目的是为了确定肝硬化患者门静脉血栓形成的危险因素

Hepatology: 较冷的天气和较少的阳光时间会增加酒精消耗和酒精性肝硬化的发生

酒精性肝硬化的风险取决于遗传和环境因素。本项研究的目的是调查气候是否会对酒精消耗及其对酒精性肝硬化的影响产生影响。

Clinical and Translational Gastro: 血清鞘脂可作为住院失代偿期肝硬化患者营养不良的生物标志物

营养不良是肝硬化发病和死亡的主要原因。尽管已经研究了多种营养状况的非侵入性测量方法,但对于早期识别肝硬化中的营养不良尚未达成共识。血清代谢组学为识别多种疾病状态的生物标志物提供了一种新方法。因此,本项研究旨在探究表征住院肝硬化患者营养不良相关代谢途径的改变,并确定疾病预后的生物标志物。

AJG:医院感染是肝硬化患者频繁住院和负面结局的主要原因

医院感染(NIs)可能是肝硬化发病率和死亡率的主要原因。本研究旨在确定NI发生的影响因素及其对住院肝硬化患者30天结局的影响。

Clin Translational Gastroenterology:NOD2突变是肝硬化细菌感染的主要易感因素

有文献报道核苷酸结合寡聚化结构域2 (NOD 2)的基因变异与肝硬化中的细菌感染(BI),特别是自发性细菌性腹膜炎和死亡率相关。因此,本项研究的目的是评估肝硬化期间NOD2变异与BI 之间的相关性。